Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. 6 February 2020. Andrew Newland.

Executive Summary

Liquid biopsy firm Angle PLC says it will progress a de novo US FDA submission for its Parsortix blood test by March. The company held a Q-submission meeting with the agency last month to discuss regulatory requirements. See what Angle CEO Andrew Newland said about it here.

“We were happy that all the critical issues that we wanted to address, were addressed, and we got the clear guidance.” – Andrew Newland, CEO, Angle PLC 

Click here for a free trial of Medtech Insight


Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts